CD40 stimulation on CLL cells
|
|
- Shannon O’Connor’
- 5 years ago
- Views:
Transcription
1 Pathways of apoptosis 0 stimulation on cells 0 stimulation on cells NC Survivin Actin ymphoid tissues in Proliferation Centres Survivin Proliferation Centres Ki7 <% Normal N p27 >9% N 0 cl-2 Aberrant immune response? he proliferating compartment Survival Proliferation CC22 (CC17) Cognitive ic elements Activation/proliferation Affinity maturation Resting Naive cells Mantle zone ight zone Dark zone 0 (I-) 1
2 cells show IGV somatic mutations () DEFINIION Accumulation of small, resting, mature + lymphocytes in peripheral blood, bone marrow, lymph nodes and spleen () omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course Indolent course Aggressive course Survival: 12-1 years Survival: 3- years herapy: No need or late herapy: Early and frequent Small ymphocytic ymphoma (S) ow-grade, indolent ymphomas Fais et al, 1998 Gastric ymphoma Chronic. pylori infection 10-20% of cancers associated with infections Direct. pylori specific cells + Stimulation Infiltrating autoreactive cells Early. pylori MA t(11;18) dependent ymphoma t(1;1)/t(1;2) C-10 mutations? ate Aggressive. pylori MA MA independent ymphoma ymphoma ransformed? MA ymphoma epatitis C iver cancer ymphoma (splenic y villous lymphocytes) V1 Adult -cell leukaemia Campylobacter ymphoma Epstein-arr virus odgkin's disease Intest. ymphoma Nasopharyngeal cancer Kaposi's sarcoma V8 Chlamydia Psitt Primary effusion lymphoma Papilloma virus Cervical cancer ymphoma Ocul. Adn. Gastric cancer elicobacter pylori Gastric lymphoma..catastrophes ususally depend upon a combination of errors. lood count, blood film and immunophenotype omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course (years vs decades) lood count, blood film and immunophenotype omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course (years vs decades) lood count, blood film and immunophenotype omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course (years vs decades) Classic Prognostic factors Classic Prognostic factors iological Prognostic factors Clinical Stage (Rai/inet) Define disease Clinical Stage (Rai/inet) Define disease β2-microglobulin Correlate with one Marrow istology extension one Marrow istology extension Serum CD23 disease burden D D Serum hymidine Kinase Staging reatment strategy New biological Prognostic factors Stage A (0) Wait and watch IGV mutational status Predict prognosis Stage (I-II) reat if progression CD38 expression at diagnosis Stage C (III-IV) reat at onset ZAP-70 expression FIS 2
3 ZAP-70, CD38 and IGV mutations Zap-70 expression is a continuum IGV genes in IGV3-21 ~ 3% of all IGV genes used in M M M M UM UM Rassenti,. Z. et al. 200 Crespo et al, 2003 IGV1-9 ~ 10% of all IGV genes used in amblin,. Z. et al Rassenti,. Z. et al ymphocytes ( + )...a distinct cell lineage? In the fetus and newborn: predominant population In the adult: in the Mantle Zone (1% of circulating cells) Natural autoantibodies production Reconstitution Experiments in the mouse Absence of somatic mutations Conventional cells produce autoantibodies hey readily appear after M Few somatic mutations = Naive Why do cells interact with? CEMOKINE P N CC22/MDC - + CC17/ARC - +/- CC/Rantes + + CC3/Mip-1! + + CC20ARC - - CC19/EC - - CC21/SC - - CC1/I CC2/eck - - CXC8/I CXC10/IP CXC9Mig - - CXC12/SDF CXC12CA CXC13/CA CXC3C1/Fractalkine - - Activated + Cells Express CCR cells: short vs long term survival CD100 and Plexin-1 in Stroma ime (days) 3
4 Scenario A: ic stimulation is an activation marker Scenario A: antigenic stimulation (auto) anti-µ Mutated IG + cell Mutated I- + cell Unmutated I-1 Unmutated IG I-2 Scenario : no CR stimulation Caligaris-Cappio et al. lood 1989; Wortis et al, PNAS 199 Scenario : auto (super) antigenic stimulation Unrelated patients carry similar CDR3 () () Case P131 IA-D2 FRA-33 IA- N13 FRA-28 CDR3 AR DAN GMDV (K)CDR3 QVWDSGSDPWV IGV3-21 DIAGNOSIS 1) Absolute cell lymphocytosis >000/ul for > weeks 2) (>30% linfociti in MO) 3) Immunophenotype - ight chain (κ/λ) restriction Characteristic phenotype: +, CD23 +, low, sigm low IA-1 P1321 FRA M Q R , +, CD ow surface Ig FRA D ---- SPA R G P32 IA-3 FRA-09 -I -R A D G FRA Q- D--- IA P D-----Y- FRA-299 N A A--- QQYNNWPPE M-G--- G obin et al, lood 2002 Ghia et al, lood 200 allek et al, lood 2008 cell clonal expansions in the elderly rasforming events Microenvironment Interactions Sequential genetic abnormalities rasforming events Microenvironment Interactions Sequential genetic abnormalities Monoclonal Gammopathy of uncertain significance (MGUS) Step 1: ransformation Step 2: Accumulation Step 3: Autonomous Growth Step 1: ransformation Step 2: Accumulation Step 3: Autonomous Growth MGUS: 1%/year MM
5 Accumulation of lymphocytes: +, CD23 +, sigm low IGV N1 IGD N2 IGJ FRA-081 C A R E Q W V R S F D Y W P3073 C A R E Q W V R V N F D Y W P23 C A R A Q W V V N F D Y W FRA-178 C A R E Q W V R F D Y W P3129 C A R E Q W D A F D Y W SPA-91 C A R A Q W V P F D Y W FRA-270 C A R E Q W V F D Y W N3088 C A R E Q W V K E F F D Y W FRA-19 C A R Q W V R D Y F D Y W N2837 C A R V Q W V R E Y F D Y W FRA-190 C A R D Q W V D Y F D Y W P39 C A R W Q W V G Y F D Y W FRA-210 C A R E Q W A K P F D Y W P1173 C A R E Q W G I K N F D Y W FRA-22 C A R I Q W G P P S F D Y W FRA-293 C A R E Q W G P F D Y W FRA-290 C A R D Q W P N N F D Y W SPA- C A R D Q W P I N Y F D Y W N17 C A R K Q W P Q Y Y F D Y W SPA- C A R A Q W S I N Y Y F D Y W omogeneous phenotype: +, CD23 +, sigm low cells in the Proliferation Centres he proliferating compartment omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course Survival Indolent course Aggressive course CD23 CC22 (CC17) Proliferation Survival: 12-1 years herapy: No or late need New biological Prognostic factors IGV mutational status CD38 expression ZAP-70 expression Genomic abnormalities Survival: 3- years herapy: Early and frequent Predict prognosis at diagnosis CD Medium only Medium ime (days) Granziero et al, 2001; Ghia et al, 2002; Granziero et al, 2003 Ki7 0 0 (I-) CDR3 analysis EAVY CAIN V D J C V J C IG CAIN IMMUNOOGY AND MAEMAICS ' 3' ' 3 ' 3 9- x 2 3 x 3-37 x 300 POENIA RECOMINAIONS POENIA RECOMINAIONS N-DIVERSIY SOMAIC MUAIONS X x - ambda ' 3 ' ' 3' Mathematical chances that two different cell clones might share the same CR ~.3 x 10 POSSIIIIES ~ 3. x 10 POSSIIIIES 2 x DIFFEREN ANIODIES 1:10-12 FR1 FR2 FR3 IGV CDR1 CDR2 IGD CDR3 IGJ 0, %
6 1, 1, 1,2 1,0 0,8 0, 0, 0,2 0,0 ZAP70 is differentially expressed in cells ZAP70 correlates with clinical course Cell Receptor (CR) β α ε δ γ ε Rassenti,. Z. et al. 200 Crespo et al, 2003 SP-7 Itk/Rlk Zap-70 ζ ζ ck Rosenwald et al 2001 Wiestner et al, 2003 Rassenti,. Z. et al. 200 PC-γ ZAP70 is expressed in normal cells ZAP70: recent/persistent activation? Scenario A: initial CR stimulation CD3+ Memory Naive GC ZAP-70 β actin ZAP-70/β -ac tin (OD ratio) CD3+ Memory Naive GC CD1+ CD1+ CD3+ ZAP-70 β actin activation Mantle zone ight zone Dark zone cell Good prognosis ad prognosis P Cells Scelzo et al, eukemia 200 ZAP-70 expression Scenario : ongoing CR stimulation Aberrant immune response? Cognitive Activation/proliferation Resting omogeneous phenotype: +, CD23 +, sigm low omogeneous phenotype: +, CD23 +, sigm low eterogeneous clinical course ic elements Indolent course Aggressive course Survival: 12-1 years Survival: 3- years herapy: No or late need herapy: Early and frequent
7 Chromosomal abnormalities in cells in the Proliferation Centres he proliferating compartment Survival CD23? CD3 mir-1a mir-1-1 p3 100 risomy 12: 1% 90 13q deletion: 3% Medium only Medium Ki AM? Proliferation CC22 (CC17) ime (days) 0 11q deletion: 18% 17p deletion: 7% Dohner et al (I-) Granziero e t al, 2001; Ghia et al, 2002; Granziero et al, 2003 Ghia et al, Sem Cancer iol 2002 Aberrant immune response? Cognitive Activation/proliferation Resting ic elements 7
Prepared by: Dr.Mansour Al-Yazji
C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationThe 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010
The 1 World Congress on Controversies in Hematology (COHEM) Rome, September 2010 Is the wait and watch philosophy still practical in the treatment of CLL even in younger patients? Expected to say NO Federico
More informationChronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo
Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas NAIVE -B LYMPHOCYTE MEMORY CELL CLL MCL FL MZL Small cell size Low proliferation
More informationIntroduction. Introduction. Lymphocyte development (maturation)
Introduction Abbas Chapter 8: Lymphocyte Development and the Rearrangement and Expression of Antigen Receptor Genes Christina Ciaccio, MD Children s Mercy Hospital January 5, 2009 Lymphocyte development
More informationGlobal warming in the leukaemia microenvironment: Chronic Lymphocytic Leukaemia (CLL) Nina Porakishvili
Global warming in the leukaemia microenvironment: Chronic Lymphocytic Leukaemia (CLL) Nina Porakishvili Working plan Case study; Epidemiology; Diagnosis; Immunobiology; Prognostication; Stratification
More informationImmunological aspects in chronic lymphocytic leukemia (CLL) development
Ann Hematol (2012) 91:981 996 DOI 10.1007/s00277-012-1460-z REVIEW ARTICLE Immunological aspects in chronic lymphocytic leukemia (CLL) development Ricardo García-Muñoz & Verónica Roldan Galiacho & Luis
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationThe development of clonality testing for lymphomas in the Bristol Genetics Laboratory. Dr Paula Waits Bristol Genetics Laboratory
The development of clonality testing for lymphomas in the Bristol Genetics Laboratory Dr Paula Waits Bristol Genetics Laboratory Introduction The majority of lymphoid malignancies belong to the B cell
More informationSupplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic
Supplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic B cells from WT Nfat2 +/+, TCL1 Nfat2 +/+ and TCL1 Nfat2
More informationPRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma
PRECURSOR LYMHPOID NEOPLASMS B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma B lymphoblastic leukaemia/lymphoma Definition: B lymphoblastic leukaemia/lymphoma is a neoplasm of precursor
More informationB cell activation and antibody production. Abul K. Abbas UCSF
1 B cell activation and antibody production Abul K. Abbas UCSF 2 Lecture outline B cell activation; the role of helper T cells in antibody production Therapeutic targeting of B cells 3 Principles of humoral
More informationFrom Pathogenesis to Treatment of Chronic Lymphocytic Leukaemia (printer-friendly)
www.medscape.com Authors and Disclosures Thorsten Zenz*, Daniel Mertens*, Ralf Küppers, Hartmut Döhner* & Stephan Stilgenbauer* *Department of Internal Medicine III, University of Ulm, Ulm 89081, Germany.
More informationMolecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU
Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU Lecture outline Time 10:00 11:00 11:15 12:10 12:20 13:15 Content Introduction to lymphoma Review of lymphocyte biology
More informationCLL Ireland Information Day Presentation
CLL Ireland Information Day Presentation 5 May 2018 Professor Patrick Thornton Consultant Haematologist, Senior Lecturer RCSI, and Clinical Director Hermitage Medical Clinic Laboratory Chronic Lymphocytic
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationMECHANISMS OF B-CELL LYMPHOMA PATHOGENESIS
MECHANISMS OF B-CELL LYMPHOMA PATHOGENESIS Ralf Küppers Abstract Chromosomal translocations involving the immunoglobulin loci are a hallmark of many types of B-cell. Other factors, however, also have important
More informationTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version: CLLBiomarkers 1.0.0.2 Protocol Posting Date: June 2017
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationFollicular Lymphoma. ced3 APOPTOSIS. *In the nematode Caenorhabditis elegans 131 of the organism's 1031 cells die during development.
Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai Follicular Lymphoma 1. Characterized by t(14:18) translocation 2. Ig heavy
More informationSession 5. Pre-malignant clonal hematopoietic proliferations. Chairs: Frank Kuo and Valentina Nardi
Session 5 Pre-malignant clonal hematopoietic proliferations Chairs: Frank Kuo and Valentina Nardi Pre-malignant clonal hematopoietic proliferations Clonal LYMPHOID proliferations: - Monoclonal gammopathy
More informationAntigen-Independent B-Cell Development Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationT cell development October 28, Dan Stetson
T cell development October 28, 2016 Dan Stetson stetson@uw.edu 441 Lecture #13 Slide 1 of 29 Three lectures on T cells (Chapters 8, 9) Part 1 (Today): T cell development in the thymus Chapter 8, pages
More informationAndrea s Final Exam Review PCB 3233 Spring Practice Final Exam
NOTE: Practice Final Exam Although I am posting the answer key for this practice exam, I want you to use this practice to gauge your knowledge, and try to figure out the right answer by yourself before
More informationT Cell Differentiation
T Cell Differentiation Ned Braunstein, MD MHC control of Immune Responsiveness: Concept Whether or not an individual makes an immune response to a particular antigen depends on what MHC alleles an individual
More informationAndrea s SI Session PCB Practice Test Test 3
Practice Test Test 3 READ BEFORE STARTING PRACTICE TEST: Remember to please use this practice test as a tool to measure your knowledge, and DO NOT use it as your only tool to study for the test, since
More informationIg light chain rearrangement: Rescue pathway
B Cell Development Ig light chain rearrangement: Rescue pathway There is only a 1:3 chance of the join between the V and J region being in frame Vk Jk Ck Non-productive Rearrangement Light chain has a
More informationAdaptive Immunity: Humoral Immune Responses
MICR2209 Adaptive Immunity: Humoral Immune Responses Dr Allison Imrie 1 Synopsis: In this lecture we will review the different mechanisms which constitute the humoral immune response, and examine the antibody
More informationMathematical models of chronic lymphocytic leukemia
Mathematical models of chronic lymphocytic leukemia Introduction to CLL Ibrutinib therapy understanding the kinetics Calculating personalized treatments Dominik Wodarz Department of Ecology and Evolutionary
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationDiagnostic Molecular Pathology of Lymphoid Neoplasms
Diagnostic Molecular Pathology of Lymphoid Neoplasms (Part II) Rational use of molecular testing in lymphomas Beirut, Lebanon Friday December 2, 2011: Hematopathology Session Adam Bagg University of Pennsylvania
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More informationInnate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil
1 The immune system The immune response The immune system comprises two arms functioning cooperatively to provide a comprehensive protective response: the innate and the adaptive immune system. The innate
More informationOverview B cell development T cell development
Topics Overview B cell development T cell development Lymphocyte development overview (Cont) Receptor diversity is produced by gene rearrangement and is random Includes specificities that will bind to
More informationFOLLICULARITY in LYMPHOMA
FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular
More informationLow-grade B-cell lymphoma
Low-grade B-cell lymphoma Patho-Basic 11. September 2018 Stephan Dirnhofer Pathology Outline Definition LPL, MBL/CLL/SLL, MCL FL Subtypes & variants Diagnosis including Grading Transformation Summary Be
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationκ λ Antigen-Independent B-Cell Development Bone Marrow Ordered Rearrangement of Ig Genes During B-Cell Development in the Bone Marrow
Antigen-Independent B-Cell Development Bone Marrow 1. DNA rearrangements establish the primary repertoire, creating diversity 2. Allelic exclusion ensures that each clone expresses a single antibody on
More informationaccumulation the blood, marrow, lymph nodes, and spleen.
Chronic Lymphocytic Leukemia accumulation of mature-appearing appearing lymphocytes in the blood, marrow, lymph nodes, and spleen. CLL cells are: monoclonal l B lymphocytes that express CD19. CD5, and
More informationT cell and Cell-mediated immunity
T cell and Cell-mediated immunity Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, it School of Medicine i Medical Research Building B815-819 Email: Lu.Linrong@gmail.com
More informationWHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
More informationmembrane form secreted form 13 aa 26 aa K K V V K K 3aa
Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai secreted form membrane form 13 aa 26 aa K K V V K K 3aa Hapten monosaccharide
More informationPathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e
Pathology #07 Mature B-Cell Neoplasm Hussein Al-Sa di Dr. Sohaib Al-Khatib 0 P a g e Thursday 18/2/2016 Our lecture today (with the next 2 lectures) will be about lymphoid tumors This is a little bit long
More informationImmune Regulation and Tolerance
Immune Regulation and Tolerance Immunoregulation: A balance between activation and suppression of effector cells to achieve an efficient immune response without damaging the host. Activation (immunity)
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationTest Utilization: Chronic Lymphocytic Leukemia
Test Utilization: Chronic Lymphocytic Leukemia Initial Evaluation Diagnostic Criteria Selection of Tests for Prognosis Response to Therapy Challenges Assessment for persistent disease Paul J. Kurtin, M.D.
More informationSheena Surindran Grand Rounds 2/15/11
Sheena Surindran Grand Rounds 2/15/11 Affects 5 12 person per million / year 5 10% associated with myeloma Median survival without treatment is 12 40 months Most commonly affected organs are kidney, heart
More informationEurekah Bioscience Collection
in Malignant 5/31/06 12:09 PM in Malignant to Leukemia and Lymphoma Eurekah Bioscience Collection in Malignant Sarah E. enrickson Elena M. artmann German Ott Andreas Rosenwald* The practice of clinical
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationImmunobiology 7. The Humoral Immune Response
Janeway Murphy Travers Walport Immunobiology 7 Chapter 9 The Humoral Immune Response Copyright Garland Science 2008 Tim Worbs Institute of Immunology Hannover Medical School 1 The course of a typical antibody
More informationFollicular Lymphoma: the WHO
Follicular Lymphoma: the WHO and the WHERE? Yuri Fedoriw, MD Associate Professor of Pathology and Laboratory Medicine Director of Hematopathology University of North Carolina Chapel Hill, NC Disclosure
More informationGeorg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria
Chronic lymphocytic Leukemia Georg Hopfinger 3. Med.Abt and LBI for Leukemiaresearch and Haematology Hanusch Krankenhaus,Vienna, Austria georg.hopfinger@wgkk.at CLL Diagnosis and Staging Risk Profile Assessment
More informationLymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationDevelopment of B and T lymphocytes
Development of B and T lymphocytes What will we discuss today? B-cell development T-cell development B- cell development overview Stem cell In periphery Pro-B cell Pre-B cell Immature B cell Mature B cell
More informationIntroduction to Immunology Part 2 September 30, Dan Stetson
Introduction to Immunology Part 2 September 30, 2016 Dan Stetson stetson@uw.edu 441 Lecture #2 Slide 1 of 26 CLASS ANNOUNCEMENT PLEASE NO TREE NUTS IN CLASS!!! (Peanuts, walnuts, almonds, cashews, etc)
More informationCLL Biology and Initial Management. Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology
CLL Biology and Initial Management Gordon D. Ginder, MD Director, Massey Cancer Center Lipman Chair in Oncology CLL- Epidemiology Most common adult leukemia 25-30% in western world Incidence in US 4.5
More informationThe Adaptive Immune Response. B-cells
The Adaptive Immune Response B-cells The innate immune system provides immediate protection. The adaptive response takes time to develop and is antigen specific. Activation of B and T lymphocytes Naive
More informationPrinciples of Adaptive Immunity
Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors
More informationShort Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia
Short Telomeres Predict Poor Prognosis in Chronic Lymphocytic Leukemia L. Yang Internal Medicine Resident University of Manitoba Supervisor: Dr. J. Johnston Prognostic factors Clinical course is unpredictable
More informationHow plasma cells develop. Deutsches Rheuma Forschungs Zentrum, Berlin Institut der Leibniz Gemeinschaft
How plasma cells develop Deutsches Rheuma Forschungs Zentrum, Berlin Institut der Leibniz Gemeinschaft 1 Plasma cells develop from activated B cells Toll Like Receptor B Cell Receptor B cell B cell microbia
More informationBone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
More informationOsteosclerotic Myeloma (POEMS Syndrome)
Osteosclerotic Myeloma (POEMS Syndrome) Osteosclerotic Myeloma (POEMS Syndrome) Synonyms Crow-Fukase syndrome Multicentric Castleman disease Takatsuki syndrome Acronym coined by Bardwick POEMS Scheinker,
More informationT cell maturation. T-cell Maturation. What allows T cell maturation?
T-cell Maturation What allows T cell maturation? Direct contact with thymic epithelial cells Influence of thymic hormones Growth factors (cytokines, CSF) T cell maturation T cell progenitor DN DP SP 2ry
More informationCommentary on the WHO Classification of Tumors of Lymphoid Tissues (2008): Indolent B Cell Lymphomas
Commentary on the WHO Classification of Tumors of Lymphoid Tissues (2008): Indolent B Cell Lymphomas The Harvard community has made this article openly available. Please share how this access benefits
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationAggressive B-Cell Lymphomas
Aggressive B-cell Lymphomas Aggressive B-Cell Lymphomas Stephen Hamilton Dutoit Institute of Pathology Aarhus Kommunehospital B-lymphoblastic lymphoma Diffuse large cell lymphoma, NOS T-cell / histiocyte-rich;
More informationUnderstanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals
Understanding your diagnosis Dr Graham Collins Consultant Haemtologist Oxford University Hospitals Common questions I get asked What is lymphoma? What subtype do I have and what does that mean? What are
More informationReactive and Neoplastic Lymphocytosis
Reactive and Neoplastic Lymphocytosis Koranda A. Walsh, VMD, BS Assistant Professor, Clinical Pathobiology University of Pennsylvania School of Veterinary Medicine PLEASE NOTE: These notes are meant as
More information1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples. Major Principles:
Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Carcinogenesis Major Principles: 1. Nonlethal genetic damage is central to
More informationThe patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:
Case History An 86 year old male was admitted to hospital with chest infection. Haematological examination subsequently revealed the following: Hb- 11.0 g/dl; WBC- 67.1 x 10^9/l; PLT- 99 x10^9/l; RBC-
More informationLymphoma and microenvironment
Lymphoma and microenvironment Valter Gattei, MD Head Clinical and Experimental Oncology Unit IRCCS Aviano (PN) % viable cells CLL cells do need microenvironmental CLL and microenvironment... interactions
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More informationCHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE
CHAPTER 9 BIOLOGY OF THE T LYMPHOCYTE Coico, R., Sunshine, G., (2009) Immunology : a short course, 6 th Ed., Wiley-Blackwell 1 CHAPTER 9 : Biology of The T Lymphocytes 1. 2. 3. 4. 5. 6. 7. Introduction
More informationHow T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do? Monoclonal antibody approach
How T cells recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about T cell function was known, but the receptor genes had not been identified
More informationSeminar. Chronic lymphocytic leukaemia
Chronic lymphocytic leukaemia G Dighiero, T J Hamblin Chronic lymphocytic leukaemia is the commonest form of leukaemia in Europe and North America, and mainly, though not exclusively, affects older individuals.
More informationA second type of TCR TCR: An αβ heterodimer
How s recognize antigen: The T Cell Receptor (TCR) Identifying the TCR: Why was it so hard to do By the early 1980s, much about function was known, but the receptor genes had not been identified Recall
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationSPECIFIC IMMUNITY = ACQUIRED IMMUNITY = ADAPTIVE IMMUNITY SPECIFIC IMMUNITY - BASIC CHARACTERISTIC
SPECIFIC IMMUNITY - BASIC CHARACTERISTIC SPECIFIC IMMUNITY = ACQUIRED IMMUNITY = ADAPTIVE IMMUNITY BASIC TERMINOLOGY SPECIFIC IMMUNITY humoral mediated with antibodies cellular mediated with T lymphocytes
More informationAutoimmunity in CLL. Anne Silva, MD Hematology Fellows Conference
Autoimmunity in CLL Anne Silva, MD Hematology Fellows Conference Case Presentation Mr. M is a 62 year old male with multiple medical problems including pulmonary sarcoidosis on steroids, was incidentally
More informationAnaemias and other Pesky Haematology Questions
Anaemias and other Pesky Haematology Questions 3 main topics How do I work out an anaemia.. That oh too common paraprotein patient. Those mildly raised lymphocyte count GP discussed patient with me over
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationPlasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
More informationPersistent lymphocytosis. Persistent lymphocytosis: are there prognostic indicators? Problem. Questions. Basic markers used to identify lymphocytes
Persistent lymphocytosis Persistent lymphocytosis: are there prognostic indicators? Paul R. Avery VMD, PhD, DACVP Marjorie Williams, DVM Anne C. Avery VMD, PhD Clinical Immunology Laboratory Colorado State
More informationThe Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D.
The Development of Lymphocytes: B Cell Development in the Bone Marrow & Peripheral Lymphoid Tissue Deborah A. Lebman, Ph.D. OBJECTIVES 1. To understand how ordered Ig gene rearrangements lead to the development
More informationT cell Receptor. Chapter 9. Comparison of TCR αβ T cells
Chapter 9 The αβ TCR is similar in size and structure to an antibody Fab fragment T cell Receptor Kuby Figure 9-3 The αβ T cell receptor - Two chains - α and β - Two domains per chain - constant (C) domain
More informationCarcinogenesis. Carcinogenesis. 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples
Carcinogenesis 1. Basic principles 2. 6 hallmark features 3. Abnormal cell proliferation: mechanisms 4. Carcinogens: examples Major Principles (cont d) 4. Principle targets of genetic damage: 4 classes
More informationChapter 11. B cell generation, Activation, and Differentiation. Pro-B cells. - B cells mature in the bone marrow.
Chapter B cell generation, Activation, and Differentiation - B cells mature in the bone marrow. - B cells proceed through a number of distinct maturational stages: ) Pro-B cell ) Pre-B cell ) Immature
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationSmall B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
More informationIntroduction. Abbas Chapter 10: B Cell Activation and Antibody Production. General Features. General Features. General Features
Introduction Abbas Chapter 10: B Cell Activation and Antibody Production January 25, 2010 Children s Mercy Hospitals and Clinics Humoral immunity is mediated by secreted antibodies (Ab) Ab function to
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationB Lymphocyte Development and Activation
Harvard-MIT Division of Health Sciences and Technology HST.176: Cellular and Molecular Immunology Course Director: Dr. Shiv Pillai 09/26/05; 9 AM Shiv Pillai B Lymphocyte Development and Activation Recommended
More informationNGS IMMUNOGENETICS IN CLL RESEARCH. Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH
NGS IMMUNOGENETICS IN CLL RESEARCH Andreas Agathangelidis Post-doc researcher Institute of Applied Biosciences, CERTH ERIC & Euroclonality-NGS workshop Rotterdam, 24 November 2017 1. NGS Immunoprofiling
More informationChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia Neil E. Kay, Terry J. Hamblin, Diane F. Jelinek, Gordon W. Dewald, John C. Byrd, Sherif Farag, Margaret Lucas, and Thomas Lin This update of early stage B-cell chronic lymphocytic
More informationCOURSE: Medical Microbiology, MBIM 650/720 - Fall TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12
COURSE: Medical Microbiology, MBIM 650/720 - Fall 2008 TOPIC: Antigen Processing, MHC Restriction, & Role of Thymus Lecture 12 FACULTY: Dr. Mayer Office: Bldg. #1, Rm B32 Phone: 733-3281 Email: MAYER@MED.SC.EDU
More informationEarly Life Intervention Diminishes Manifestations. NOD.H-2 h4 mice. Tamer Mahmoud. Rachel Ettinger. Postdoctoral Fellow.
Early Life Intervention Diminishes Manifestations of Sjögren's Syndrome in NOD.H-2 h4 mice Tamer Mahmoud Postdoctoral Fellow Rachel Ettinger Senior Scientist Clinical Manifestations of Sjögren s Syndrome
More information